UCB S.A. UNSP.ADR 1/2 (UNC0) - Net Assets
Based on the latest financial reports, UCB S.A. UNSP.ADR 1/2 (UNC0) has net assets worth €10.87 Billion EUR (≈ $12.70 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€18.16 Billion ≈ $21.23 Billion USD) and total liabilities (€7.29 Billion ≈ $8.52 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore UCB S.A. UNSP.ADR 1/2 cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €10.87 Billion |
| % of Total Assets | 59.85% |
| Annual Growth Rate | 6.69% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.72 |
UCB S.A. UNSP.ADR 1/2 - Net Assets Trend (2021–2025)
This chart illustrates how UCB S.A. UNSP.ADR 1/2's net assets have evolved over time, based on quarterly financial data. Also explore UCB S.A. UNSP.ADR 1/2 asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for UCB S.A. UNSP.ADR 1/2 (2021–2025)
The table below shows the annual net assets of UCB S.A. UNSP.ADR 1/2 from 2021 to 2025. For live valuation and market cap data, see UCB S.A. UNSP.ADR 1/2 (UNC0) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €10.87 Billion ≈ $12.70 Billion |
+8.36% |
| 2024-12-31 | €10.03 Billion ≈ $11.72 Billion |
+11.74% |
| 2023-12-31 | €8.97 Billion ≈ $10.49 Billion |
-0.98% |
| 2022-12-31 | €9.06 Billion ≈ $10.60 Billion |
+8.08% |
| 2021-12-31 | €8.39 Billion ≈ $9.80 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to UCB S.A. UNSP.ADR 1/2's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 37.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €8.68 Billion | 79.87% |
| Other Components | €2.19 Billion | 20.13% |
| Total Equity | €10.87 Billion | 100.00% |
UCB S.A. UNSP.ADR 1/2 Competitors by Market Cap
The table below lists competitors of UCB S.A. UNSP.ADR 1/2 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Flex Ltd
F:FXI
|
$44.89 Billion |
|
Exelon Corporation
NASDAQ:EXC
|
$44.93 Billion |
|
Nebius Group N.V.
NASDAQ:NBIS
|
$44.95 Billion |
|
Cheniere Energy Inc
NYSE MKT:LNG
|
$44.96 Billion |
|
Fifth Third Bancorp
NASDAQ:FITB
|
$44.71 Billion |
|
China Citic Bank Corp Ltd Class A
SHG:601998
|
$44.62 Billion |
|
UCB SA
BR:UCB
|
$44.56 Billion |
|
Montage Technology Co Ltd
SHG:688008
|
$44.54 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in UCB S.A. UNSP.ADR 1/2's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,029,000,000 to 10,867,000,000, a change of 838,000,000 (8.4%).
- Net income of 1,558,000,000 contributed positively to equity growth.
- Dividend payments of 264,000,000 reduced retained earnings.
- Share repurchases of 121,000,000 reduced equity.
- Other factors decreased equity by 335,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.56 Billion | +14.34% |
| Dividends Paid | €264.00 Million | -2.43% |
| Share Repurchases | €121.00 Million | -1.11% |
| Other Changes | €-335.00 Million | -3.08% |
| Total Change | €- | 8.36% |
Book Value vs Market Value Analysis
This analysis compares UCB S.A. UNSP.ADR 1/2's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.10x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.71x to 2.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €44.33 | €120.00 | x |
| 2022-12-31 | €47.81 | €120.00 | x |
| 2023-12-31 | €47.29 | €120.00 | x |
| 2024-12-31 | €52.77 | €120.00 | x |
| 2025-12-31 | €57.09 | €120.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently UCB S.A. UNSP.ADR 1/2 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.34%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.13%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.67x
- Recent ROE (14.34%) is above the historical average (9.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 12.62% | 18.31% | 0.41x | 1.69x | €219.40 Million |
| 2022 | 4.61% | 7.58% | 0.35x | 1.75x | €-488.40 Million |
| 2023 | 3.82% | 6.53% | 0.34x | 1.73x | €-554.50 Million |
| 2024 | 10.62% | 17.31% | 0.35x | 1.73x | €62.10 Million |
| 2025 | 14.34% | 20.13% | 0.43x | 1.67x | €471.30 Million |
Industry Comparison
This section compares UCB S.A. UNSP.ADR 1/2's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $223,512,703
- Average return on equity (ROE) among peers: -29.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| UCB S.A. UNSP.ADR 1/2 (UNC0) | €10.87 Billion | 12.62% | 0.67x | $44.84 Billion |
| PROQR THERAPEUTICS EO-04 (0PQ) | $49.37 Million | -85.44% | 1.28x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $-303.75 Million | 0.00% | 0.00x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $212.27 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $344.93 Million | -8.14% | 0.08x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $1.82 Billion |
| BioNTech SE (22UA) | $31.86 Million | 0.00% | 11.24x | $20.05 Billion |
About UCB S.A. UNSP.ADR 1/2
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthr… Read more